Studying Dexmedetomidine and Esketamine to Reduce Bladder Discomfort After Transurethral Surgery

What this Trial Is About

Catheter-related bladder discomfort CRBD is a common issue for patients waking up from general anesthesia with a urinary catheter, especially after transurethral urological surgeries. This trial explores how dexmedetomidine, esketamine, and their combination may affect the occurrence of CRBD. The study is designed as a 2x2 factorial randomized trial to observe these effects in patients undergoing surgeries like transurethral resection of bladder tumor or prostate. Participants are randomly assigned to one of four groups a placebo group receiving normal saline, a dexmedetomidine group receiving 0.5 bcgkg, an esketamine group receiving 0.25 mgkg, or a combination group receiving both drugs. Each treatment is infused intravenously at a set rate after anesthesia induction but before surgery. The trial uses triple masking and aims to compare the incidence of CRBD among these groups. During the study, participants will be monitored for CRBD incidence and severity within 24 hours after surgery, along with pain intensity, sleep quality, patient satisfaction, anxiety, and depression at various time points. Assessments include subjective sleep quality on the night of surgery and follow-up evaluations up to 30 days after surgery. The study tracks these outcomes to understand how the treatments influence CRBD and related post-surgical recovery factors.

Effect of Dexmedetomidine and Esketamine on Catheter-related Bladder Discomfort